• Cougar Biotechnology Inc., of Los Angeles, has begun a Phase III trial (COU-AA-302) of its lead drug candidate CB7630 (abiraterone acetate) in patients with chemotherapy-naïve castration-resistant prostate cancer. The randomized, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic CRPC who have not yet received treatment with chemotherapy is expected to enroll approximately 1,000 patients randomized (1:1) to receive either CB7630 plus prednisone or placebo plus prednisone. The co-primary endpoints are progression-free survival and overall survival.

• Genta Inc., of Berkeley Heights, N.J., updated the company's Phase III AGENDA trial of Genasense (oblimersen sodium) Injection in advanced melanoma, showing comparable demographics compared to a previous trial. A data monitoring committee will conduct its final review of safety and futility analysis in May, and data will be announced next fall.

• Protox Therapeutics Inc., of Vancouver, British Columbia, said a Phase II study of PRX302 in patients with moderate to severe benign prostatic hyperplasia showed it is safe and well tolerated and provides dramatic improvements in International Prostate Symptom Scores and Quality of Life, which were observed along with reductions in prostate volume. Based on the results, the company has begun patient enrollment in a randomized, double-blinded, placebo-controlled Phase II trial called TRIUMPH. Top-line results are expected before the end of this year.

• Stallergenes SA, of Antony, France, said the first year outcome of its Phase IIb/III trial (VO 57.07) on a sublingual house dust mite desensitization tablet showed the efficacy of house dust mites allergen in treating perennial allergic rhinitis. Data showed an unexpected quick onset of action and good safety profile, the company said.